SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Behavioral Disorders Drug Development Pipeline Review, 2017 - Research and Markets
[October 12, 2017]

Behavioral Disorders Drug Development Pipeline Review, 2017 - Research and Markets


The "Behavioral Disorders Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.

The report, "Behavioral Disorders Drug Development Pipeline Review, 2017" provides an overview of the behavioral disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for behavioral disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publicatons to have happened in the field of behavioral disorders?

Key Topics Covered:

1 Table of Contents


2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

  1. 4D Pharma PLC
  2. 4P-Pharma SAS (News - Alert)
  3. APeT Holding BV
  4. AbbVie Inc
  5. Addex Therapeutics Ltd
  6. Amarantus Bioscience Holdings Inc
  7. Amorsa Therapeutics Inc
  8. Anima Biotech Ltd
  9. BCWorld Pharm Co Ltd
  10. BioCrea GmbH
  11. Curemark LLC
  12. DRI Biosciences Corp
  13. DURECT Corp
  14. Eli Lilly and Company
  15. F. Hoffmann-La Roche Ltd
  16. GW Pharmaceuticals Plc
  17. H. Lundbeck A/S
  18. Heptares Therapeutics Ltd
  19. Luc Therapeutics Inc
  20. MedDay SA
  21. Merck & Co Inc
  22. Neos Therapeutics Inc
  23. NeuroDerm Ltd
  24. Novartis AG
  25. Noven Pharmaceuticals Inc
  26. Omeros Corp
  27. OptiNose US Inc
  28. Otsuka Pharmaceutical Co Ltd
  29. Sumitomo Dainippon Pharma Co Ltd
  30. Sunovion Pharmaceuticals Inc
  31. Supernus Pharmaceuticals Inc
  32. Taisho Pharmaceutical Holdings Co Ltd
  33. Tris Pharma Inc

For more information about this report visit https://www.researchandmarkets.com/research/6srmq9/behavioral


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy